Aurisco Pharmaceutical Hits Day Low of CNY 24.10 Amid Price Pressure

Aurisco Pharmaceutical Co. experienced a significant decline in its stock performance on March 23, 2026, with a drop of 6.01%. The stock reached an intraday low of CNY 24.10, reflecting a challenging day for the midcap pharmaceutical and biotechnology company. In terms of performance metrics, Aurisco's one-week performance stands at -8.03%, while its one-month performance is down by 8.1%. Over the past year, however, the company has managed to achieve a positive return of 18.7%, outperforming the China Shanghai Composite, which recorded a 13.33% increase during the same period. Despite the recent downturn, Aurisco maintains a return on equity (ROE) of 16.35% and a price-to-book ratio of 3.73, indicating a fair valuation. The company also boasts a dividend yield of 1.3%. However, its inventory turnover ratio is at a low of 1.1 times, and the debtors turnover ratio is recorded at 4.24 times, suggesting areas for improvement in operational efficiency. Overall, Aurisco's current market position reflects a mix of strengths and challenges within the competitive pharmaceutical landscape.